Compare Stocks: AUTL, SRPT, MESO, and BHVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.86	$2.02	$1.18 ▼ $2.58	$495.06M	2.1	1.54 million shs	1.77 million shs
BHVN Biohaven	$13.28 +0.0%	$14.21	$7.48 ▼ $18.57	$2.00B	1.28	3.05 million shs	1.53 million shs
MESO Mesoblast	$14.87 +2.6%	$15.92	$13.05 ▼ $21.50	$1.88B	2.12	186,980 shs	158,024 shs
SRPT Sarepta Therapeutics	$18.64 -0.9%	$18.87	$14.68 ▼ $25.32	$1.99B	0.27	2.92 million shs	1.37 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+0.27%	-4.12%	-20.51%	+16.25%	+19.23%
BHVN Biohaven	+2.38%	-6.54%	-13.82%	-10.11%	-11.41%
MESO Mesoblast	-4.10%	-6.33%	-16.86%	+7.17%	-8.58%
SRPT Sarepta Therapeutics	+0.70%	-6.65%	-9.88%	+4.62%	+2.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.86	$2.02	$1.18 ▼ $2.58	$495.06M	2.1	1.54 million shs	1.77 million shs
BHVN Biohaven	$13.28 +0.0%	$14.21	$7.48 ▼ $18.57	$2.00B	1.28	3.05 million shs	1.53 million shs
MESO Mesoblast	$14.87 +2.6%	$15.92	$13.05 ▼ $21.50	$1.88B	2.12	186,980 shs	158,024 shs
SRPT Sarepta Therapeutics	$18.64 -0.9%	$18.87	$14.68 ▼ $25.32	$1.99B	0.27	2.92 million shs	1.37 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	+0.27%	-4.12%	-20.51%	+16.25%	+19.23%
BHVN Biohaven	+2.38%	-6.54%	-13.82%	-10.11%	-11.41%
MESO Mesoblast	-4.10%	-6.33%	-16.86%	+7.17%	-8.58%
SRPT Sarepta Therapeutics	+0.70%	-6.65%	-9.88%	+4.62%	+2.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.86	Moderate Buy	$10.00	437.63% Upside
BHVN Biohaven	2.59	Moderate Buy	$18.69	40.77% Upside
MESO Mesoblast	2.33	Hold	$39.00	162.27% Upside
SRPT Sarepta Therapeutics	2.10	Hold	$24.07	29.11% Upside

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, MESO, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform
9/24/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/24/2026	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/23/2026	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/18/2026	BHVN Biohaven	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
9/9/2026	SRPT Sarepta Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/8/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$23.00 ➝ $19.00
8/28/2026	BHVN Biohaven	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/28/2026	BHVN Biohaven	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$117.39M	4.22	N/A	N/A	$0.67 per share	2.78
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
MESO Mesoblast	$120.25M	16.06	N/A	N/A	$4.38 per share	3.39
SRPT Sarepta Therapeutics	$2.20B	0.90	N/A	N/A	$10.89 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	10/29/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
MESO Mesoblast	-$57.50M	-$0.28	N/A	41.31	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	10.24	0.27	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest AUTL, SRPT, MESO, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
7/31/2026	Q4 2026	MESO Mesoblast	N/A	-$0.0660	N/A	-$0.0660	N/A	$34.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
BHVN Biohaven	21.23	4.73	4.73
MESO Mesoblast	0.19	2.43	2.09
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BHVN Biohaven	88.78%
MESO Mesoblast	1.43%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BHVN Biohaven	13.80%
MESO Mesoblast	18.80%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
BHVN Biohaven	274	151.04 million	130.20 million	Optionable
MESO Mesoblast	108	129.88 million	105.46 million	Optionable
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable

AUTL, SRPT, MESO, and BHVN Headlines

Recent News About These Companies

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT), BioNTech SE (BNTX) and AgomAb Therapeutics NV ADR (AGMB)

September 29 at 5:08 PM | theglobeandmail.com

Needham & Company LLC Reaffirms Underperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)

September 28 at 8:07 AM | americanbankingnews.com

Sarepta Therapeutics' (SRPT) Underperform Rating Reiterated at Needham & Company LLC

September 28 at 8:05 AM | marketbeat.com

Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

September 26 at 6:01 PM | finance.yahoo.com

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

September 25, 2026 | finance.yahoo.com

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

September 25, 2026 | businesswire.com

Sarepta to present Phase 4 Duchenne drug data at neuromuscular meeting

September 24, 2026 | streetinsider.com

Jefferies on Sarepta Therapeutics (SRPT): 'The risk/reward seems favorable'

September 24, 2026 | streetinsider.com

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

September 24, 2026 | finance.yahoo.com

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

September 24, 2026 | businesswire.com

Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute

September 23, 2026 | tipranks.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.1% - Time to Sell?

September 23, 2026 | marketbeat.com

Sarepta Therapeutics Drops 7.1% Amid Sector-Wide Selling

September 23, 2026 | news.alphastreet.comN

Bank of America Corp DE Purchases Shares of 2,055,985 Sarepta Therapeutics, Inc. $SRPT

September 22, 2026 | marketbeat.com

Sarepta Therapeutics stock gains analyst support after mixed rating signals

September 20, 2026 | ad-hoc-news.deA

Sarepta Therapeutics stock holds near USD 19.76 after analyst reset

September 19, 2026 | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

September 18, 2026 | marketbeat.com

Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

September 16, 2026 | marketbeat.com

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

September 15, 2026 | finance.yahoo.com

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

September 15, 2026 | marketbeat.com

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, MESO, and BHVN Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.86 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.02 (+0.86%)

As of 07:42 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Biohaven NYSE:BHVN

$13.28 +0.01 (+0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$13.18 -0.10 (-0.72%)

As of 07:30 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Mesoblast NASDAQ:MESO

$14.87 +0.37 (+2.55%)

Closing price 04:00 PM Eastern

Extended Trading

$14.86 -0.01 (-0.10%)

As of 07:30 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Sarepta Therapeutics NASDAQ:SRPT

$18.64 -0.16 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$18.83 +0.19 (+1.02%)

As of 07:30 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, MESO, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, SRPT, MESO, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, SRPT, MESO, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, MESO, and BHVN Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Mesoblast NASDAQ:MESO

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUTL, SRPT, MESO, and BHVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUTL, SRPT, MESO, and BHVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUTL, SRPT, MESO, and BHVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, SRPT, MESO, and BHVN Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Biohaven NYSE:BHVN

Mesoblast NASDAQ:MESO

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools